Patients' preferences for the management of non-metastatic prostate cancer: discrete choice experiment

Abstract Objective To establish which attributes of conservative treatments for prostate cancer are most important to men. Design Discrete choice experiment. Setting Two London hospitals. Participants 129 men with non-metastatic prostate cancer, mean age 70 years; 69 of 118 (58%) with T stage 1 or 2 cancer at diagnosis. Main outcome measures Men's preferences for, and trade-offs between, the attributes of diarrhoea, hot flushes, ability to maintain an erection, breast swelling or tenderness, physical energy, sex drive, life expectancy, and out of pocket expenses. Results The men's responses to changes in attributes were all statistically significant. When asked to assume a starting life expectancy of five years, the men were willing to make trade-offs between life expectancy and side effects. On average, they were most willing to give up life expectancy to avoid limitations in physical energy (mean three months) and least willing to trade life expectancy to avoid hot flushes (mean 0.6 months to move from a moderate to mild level or from mild to none). Conclusions Men with prostate cancer are willing to participate in a relatively complex exercise that weighs up the advantages and disadvantages of various conservative treatments for their condition. They were willing to trade off some life expectancy to be relieved of the burden of troublesome side effects such as limitations in physical energy.

[1]  Stirling Bryan,et al.  Structural reliability of conjoint measurement in health care: an empirical investigation , 2002 .

[2]  M. Buxton,et al.  Preference measurement using conjoint methods: an empirical investigation of reliability. , 2000, Health economics.

[3]  P. Walsh Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 2000, The Journal of urology.

[4]  M Ryan,et al.  Using conjoint analysis to elicit preferences for health care , 2000, BMJ : British Medical Journal.

[5]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[6]  J. Adolfsson The Natural History of Early Prostate Cancer and the Impact of Endocrine Treatment , 1999, European Urology.

[7]  M. Buxton,et al.  Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. , 1998, Health economics.

[8]  T. Tammela,et al.  Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. , 1998, Urology.

[9]  S G Pauker,et al.  The toss-up. , 1981, The New England journal of medicine.

[10]  D P Byar,et al.  Orchiectomy for advanced prostatic carcinoma. A reevaluation. , 1973, Urology.